NasdaqCM - Delayed Quote USD

Fortress Biotech, Inc. (FBIO)

1.7900 -0.0200 (-1.10%)
At close: April 24 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Lindsay Allan Rosenwald Executive Chairman, President & CEO 212.66k -- 1955
Mr. David Jin CFO & Head of Corporate Development 407.33k -- 1991
Mr. Michael S. Weiss Esq. Executive Vice Chairman of Strategic Development & Director 182.66k -- 1966
Mr. Samuel Berry General Counsel & Corporate Secretary -- -- --
Dr. George C. Avgerinos Senior Vice President of Biologics Operations 386.49k -- 1954

Fortress Biotech, Inc.

1111 Kane Concourse
Suite 301
Bay Harbor Islands, FL 33154
United States
781 652 4500 https://www.fortressbiotech.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
186

Description

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Corporate Governance

Fortress Biotech, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 7; Board: 10; Shareholder Rights: 4; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 13, 2024 - May 17, 2024
Fortress Biotech, Inc. Earnings Call

Related Tickers

MBIO Mustang Bio, Inc.
0.3501
-2.67%
 
ATXI Avenue Therapeutics, Inc.
0.0943
-29.63%
 
SLN Silence Therapeutics plc
22.27
-1.07%
 
CKPT Checkpoint Therapeutics, Inc.
1.4400
+0.35%
 
EYEN Eyenovia, Inc.
0.5835
+7.54%
 
OCUP Ocuphire Pharma, Inc.
1.5300
-0.65%
 
NRXP NRx Pharmaceuticals, Inc.
3.1200
+2.30%
 
TCON TRACON Pharmaceuticals, Inc.
1.8900
+2.16%
 
ALT Altimmune, Inc.
7.08
-6.47%
 
TERN Terns Pharmaceuticals, Inc.
4.7500
+1.28%